Table 1:
Pretreatment Characteristics (Answered all 15 questions on IIEF and FACE at baseline)
| IIEF | p-value | FACE | p-value | |||
|---|---|---|---|---|---|---|
| 3D-CRT/IMRT 70.2 Gy (n=572) | 3D-CRT/IMRT 79.2 Gy (n=572) | 3D-CRT/IMRT 79.2 Gy (n=564) | 3D-CRT/IMRT 79.2 Gy (n=559) | |||
| Age(years) | ||||||
| Median | 70 | 70.5 | 71 | 71 | ||
| Min - Max | 33 – 86 | 49 – 87 | 43 – 86 | 50 – 87 | ||
| Q1 - Q3 | 64 – 74 | 65 – 74 | 0.44 | 64.5 – 74 | 64 – 74 | 0.97 |
| Race | ||||||
| White | 493 ( 86.2%) | 477 ( 83.4%) | 482 ( 85.5%) | 457 ( 81.8%) | ||
| Black | 61 ( 10.7%) | 70 ( 12.2%) | 61 ( 10.8%) | 78 ( 14.0%) | ||
| Other | 18 ( 3.1%) | 25 ( 4.4%) | 0.36 | 21 ( 3.7%) | 24 ( 4.3%) | 0.23 |
| Ethnicity | ||||||
| Hispanic or Latino | 17 ( 3.0%) | 16 ( 2.8%) | 19 ( 3.4%) | 14 ( 2.5%) | ||
| Not Hispanic or Latino | 521 ( 91.1%) | 531 ( 92.8%) | 515 ( 91.3%) | 524 ( 93.7%) | ||
| Unknown | 34 ( 5.9%) | 25 ( 4.4%) | 0.47 | 30 ( 5.3%) | 21 ( 3.8%) | 0.30 |
| Zubrod Performance Status | ||||||
| 0 | 523 ( 91.4%) | 535 ( 93.5%) | 514 ( 91.1%) | 515 ( 92.1%) | ||
| 1 | 49 ( 8.6%) | 37 ( 6.5%) | 0.18 | 50 ( 8.9%) | 44 ( 7.9%) | 0.55 |
| PSA(Study Entry) | ||||||
| <10 ng/ml | 397 ( 69.4%) | 406 ( 71.0%) | 403 ( 71.5%) | 400 ( 71.6%) | ||
| 10-<15 ng/ml | 154 ( 26.9%) | 134 ( 23.4%) | 140 ( 24.8%) | 126 ( 22.5%) | ||
| 15–20 ng/ml | 21 ( 3.7%) | 32 ( 5.6%) | 0.15 | 21 ( 3.7%) | 33 ( 5.9%) | 0.18 |
| Gleason | ||||||
| 2–6 | 91 ( 15.9%) | 89 ( 15.6%) | 78 ( 13.8%) | 84 ( 15.0%) | ||
| 7 | 481 ( 84.1%) | 483 ( 84.4%) | 0.87 | 486 ( 86.2%) | 475 ( 85.0%) | 0.57 |
| T Stage | ||||||
| T1 | 331 ( 57.9%) | 315 ( 55.1%) | 323 ( 57.3%) | 310 ( 55.5%) | ||
| T2 | 241 ( 42.1%) | 257 ( 44.9%) | 0.34 | 241 ( 42.7%) | 249 ( 44.5%) | 0.54 |
| Urinary incontinence at study entry(severity, physician reported ) | ||||||
| GRADE 0 | 544 ( 95.1%) | 537 ( 93.9%) | 540 ( 95.7%) | 522 ( 93.4%) | ||
| GRADE 1 | 23 ( 4.0%) | 29 ( 5.1%) | 19 ( 3.4%) | 29 ( 5.2%) | ||
| GRADE 2 | 5 ( 0.9%) | 4 ( 0.7%) | 5 ( 0.9%) | 5 ( 0.9%) | ||
| GRADE 3 | 0 ( 0.0%) | 1 ( 0.2%) | 0 ( 0.0%) | 1 ( 0.2%) | ||
| Unknown | 0 ( 0.0%) | 1 ( 0.2%) | 0.43* | 0 ( 0.0%) | 2 ( 0.4%) | 0.13* |
| Urinary frequency/urgency at study entry(severity, physician reported) | ||||||
| GRADE 0 | 359 ( 62.8%) | 382 ( 66.8%) | 354 ( 62.8%) | 368 ( 65.8%) | ||
| GRADE 1 | 175 ( 30.6%) | 162 ( 28.3%) | 170 ( 30.1%) | 162 ( 29.0%) | ||
| GRADE 2 | 36 ( 6.3%) | 27 ( 4.7%) | 37 ( 6.6%) | 27 ( 4.8%) | ||
| GRADE 3 | 1 ( 0.2%) | 1 ( 0.2%) | 2 ( 0.4%) | 1 ( 0.2%) | ||
| Unknown | 1 ( 0.2%) | 0 ( 0.0%) | 0.17* | 1 ( 0.2%) | 1 ( 0.2%) | 0.28* |
| RT modality | ||||||
| 3D-CRT | 378 ( 66.1%) | 386 ( 67.5%) | 353 ( 62.6%) | 344 ( 61.5%) | ||
| IMRT | 194 ( 33.9%) | 186 ( 32.5%) | 0.62 | 211 ( 37.4%) | 215 ( 38.5%) | 0.72 |
Q1 = first quartile; Q3 = third quartile.
*
Chi-square for urinary incontinence and urinary frequency/urgency at study entry is Grade 0 vs. Non Grade 0.